GLP3-R (LY3437943) is an investigational triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Studied in Phase 3 clinical trials across escalating dose cohorts — available in 10mg vials to support full-scale research protocols from initial titration through advanced study phases.